About this trial
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease.
Who can take part?
Adults aged 18 or older who:
Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved?
Participants will:
Give a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \& Risks
This research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants.
There are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK.
Who is funding the study? The study is funded by Rosetrees and Stoneygate Trust.
Contact Information Email: [email protected] Phone: +44 (0)20 7594 3396
Eligibility criteria
Qualifiers
Males and females
Adult participants ≥ 18 years old
Histologically or radiologically-confirmed* hepatocellular carcinoma or cholangiocarcinoma (participants with liver cancer)
Liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders)
Disqualifiers
Active infection, or receiving immunosuppressive medications, within the preceding eight weeks
History of another cancer within the previous five years
Previous liver resection
Already received chemotherapy, radiotherapy or surgery for their liver cancer
Trial design
Treatments tested in this trial
- Not listed